• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Publications

Publications

Featured publications

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

March 7, 2020 | Antiviral Research
Susan E Sloan et al.

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

Susan E Sloan, Kristy J Szretter, Bharathi Sundaresh, Kristin M Narayan, Patrick F Smith, David Skurnik, Sylvain Bedard, José M Trevejo, David Oldach, Zachary Shriver

>READ

Quantifying the nativeness of antibody sequences using long short-term memory networks

December 31, 2019 | Protein Engineering, Design, and Selection
Andrew M Wollacott et al.

Quantifying the nativeness of antibody sequences using long short-term memory networks

Andrew M Wollacott, Chonghua Xue, Qiuyuan Qin, June Hua, Tanggis Bohnuud, Karthik Viswanathan, Vijaya B Kolachalama

>READ

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

March 16, 2019 | Kidney International
James R Myette et al.

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

James R Myette, Toshiki Kano, Hitoshi Suzuki, Susan E Sloan, Kristy J Szretter, Boopathy Ramakrishnan, Hedy Adari, Ketan D Deotale, Frank Engler, Zachary Shriver, Andrew M Wollacott, Yusuke Suzuki, Brian J G Pereira

>READ

Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria

September 14, 2018 | Chembiochem: A European Journal of Chemical Biology
Fayçal Touti et al.

Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria

Fayçal Touti, Guillaume Lautrette, Kenneth D Johnson, James C Delaney, Andrew Wollacott, Hamid Tissire, Karthik Viswanathan, Zachary Shriver, Surin K Mong, Alexander J Mijalis, Obadiah J Plante, Bradley L Pentelute

>READ

Extending human IgG half-life using structure-guided design.

May 3, 2018 | mAbs
Brian J. Booth et al.

Extending human IgG half-life using structure-guided design.

Brian J. Booth, Boopathy Ramakrishnan, Kristin Narayan, Andrew M. Wollacott ,Gregory J. Babcock, Zachary Shriver & Karthik Viswanathan

>READ

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.

February 9, 2018 | PLoS Neglected Tropical Diseases
Yadunanda Budigi et al.

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.

Yadunanda Budigi, Eugenia Z Ong, Luke N Robinson, Li Ching Ong, Kirk J Rowley, Alexander Winnett, Hwee Cheng Tan, Sven Hobbie, Zachary Shriver, Gregory J Babcock, Sylvie Alonso, Eng Eong Ooi

>READ

Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.

May 18, 2017 | Antiviral Research
Eugenia Z Ong et al.

Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates.

Eugenia Z Ong, Yadunanda Budigi, Hwee Cheng Tan, Luke N Robinson, Kirk J Rowley, Alexander Winnett, Sven Hobbie, Zachary Shriver, Gregory J Babcock, Eng Eong Ooi

>READ

A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

October 14, 2016 | https://pubmed.ncbi.nlm.nih.gov/27751627/
Boopathy Ramakrishnan et al.

A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Boopathy Ramakrishnan, Karthik Viswanathan, Kannan Tharakaraman, Vlado Dančík, Rahul Raman, Gregory J Babcock, Zachary Shriver, Ram Sasisekharan

>READ

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.

March 25, 2016 | Antimicrobial Agents and Chemotherapy
Tatiana Baranovich et al.

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Tatiana Baranovich, Jeremy C Jones, Marion Russier, Peter Vogel, Kristy J Szretter, Susan E Sloan, Patrick Seiler, Jose M Trevejo, Richard J Webby, Elena A Govorkova

>READ

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

March 5, 2016 | EBioMedicine
Andrew M. Wollacott et al.

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

Andrew M. Wollacott, Maciej F. Boni, Kristy J. Szretter, Susan E. Sloan, Mona Yousofshahi, Karthik Viswanathan, Sylvain Bedard, Catherine A. Hay, Patrick F. Smith, Zachary Shriver, and Jose M. Trevejo

>READ

A broadly neutralizing human monoclonal antibody is effective against H7N9.

August 7, 2015 | PNAS
Kannan Tharakaraman et al.

A broadly neutralizing human monoclonal antibody is effective against H7N9.

Kannan Tharakaraman, Vidya Subramanian, Karthik Viswanathan, Susan Sloan, Hui-Ling Yen, Dale L. Barnard, Y. H. Connie Leung, Kristy J. Szretter, Tyree J. Koch, James C. Delaney, Gregory J. Babcock, Gerald N. Wogan, Ram Sasisekharan, and Zachary Shriver

>READ

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.

July 30, 2015 | Cell
Luke N. Robinson et al.

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.

Luke N. Robinson, Kannan Tharakaraman, Kirk J. Rowley, Vivian V. Costa, Kuan Rong Chan, Yee Hwa Wong, Li Ching Ong, Hwee Cheng Tan, Tyree Koch, David Cain, Rama Kirloskar, Karthik Viswanathan, Chong Wai Liew, Hamid Tissire, Boopathy Ramakrishnan, James R. Myette, Gregory J. Babcock, V. Sasisekharan, Sylvie Alonso, Jianzhu Chen, Julien Lescar, Zachary Shriver, Eng Eong Ooi, Ram Sasisekharan

>READ

Antibody-Based Strategies to Prevent and Treat Influenza.

July 13, 2015 | Frontiers in Immunology
Zachary Shriver et al.

Antibody-Based Strategies to Prevent and Treat Influenza.

Zachary Shriver, Jose M Trevejo, Ram Sasisekharan

>READ
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design